Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination
Crystal Zheng, Indrani Kar, Claire Kaori Chen, et al.
CNS Drugs (2020) Vol. 34, Iss. 9, pp. 879-896
Open Access | Times Cited: 92

Showing 26-50 of 92 citing articles:

Association of Disease-Modifying Therapies with COVID-19 Susceptibility and Severity in Patients with Multiple Sclerosis: A Systematic Review and Network Meta-Analysis
Mahdi Barzegar, Shakiba Houshi, Erfan Sadeghi, et al.
Multiple Sclerosis International (2022) Vol. 2022, pp. 1-13
Open Access | Times Cited: 15
COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review
Fioravante Capone, Francesco Motolese, Tiziano Luce, et al.
Multiple Sclerosis and Related Disorders (2021) Vol. 48, pp. 102734-102734
Open Access | Times Cited: 19
Impact of the COVID‐19 pandemic on access to healthcare services amongst patients with multiple sclerosis in the Lazio region, Italy
Paola Colais, Silvia Cascini, M Balducci, et al.
European Journal of Neurology (2021) Vol. 28, Iss. 10, pp. 3403-3410
Open Access | Times Cited: 19
Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab
Rocco Capuano, Giovanna Donnarumma, Alvino Bisecco, et al.
Therapeutic Advances in Neurological Disorders (2021) Vol. 14
Open Access | Times Cited: 19
SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine
Masoud Etemadifar, Nahad Sedaghat, Hosein Nouri, et al.
Multiple Sclerosis and Related Disorders (2021) Vol. 57, pp. 103417-103417
Open Access | Times Cited: 19
Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis
Christina Woopen, Katharina Schleußner, Katja Akgün, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 18
COVID-19 vaccine hesitancy in Iranian patients with multiple sclerosis
Naghmeh Abbasi Kasbi, Fereshteh Ghadiri, Abdorreza Naser Moghadasi, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 60, pp. 103723-103723
Open Access | Times Cited: 13
Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study
Antonio Rosario Ziello, Cristina Scavone, Maria Elena Di Battista, et al.
Brain Sciences (2021) Vol. 11, Iss. 7, pp. 890-890
Open Access | Times Cited: 17
Surviving a global pandemic: The experience of depression, anxiety, and loneliness among individuals with multiple sclerosis
Lauren B. Strober, Edgar Weber, Anthony H. Lequerica, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 58, pp. 103497-103497
Open Access | Times Cited: 11
Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide
Carlo Tornatore, Heinz Wiendl, Alex L. Lublin, et al.
Frontiers in Neurology (2022) Vol. 13
Open Access | Times Cited: 10
Potential Risks and Benefits of Multiple Sclerosis Immune Therapies in the COVID-19 Era: Clinical and Immunological Perspectives
Vikram Bhise, Suhayl Dhib‐Jalbut
Neurotherapeutics (2021) Vol. 18, Iss. 1, pp. 244-251
Open Access | Times Cited: 13
Multiple Sclerosis, COVID-19 and Vaccines: Making the Point
Simona Toscano, Clara Grazia Chisari, Francesco Patti
Neurology and Therapy (2021) Vol. 10, Iss. 2, pp. 627-649
Open Access | Times Cited: 13
Anti-inflammatory Therapy by Cholinergic and Purinergic Modulation in Multiple Sclerosis Associated with SARS-CoV-2 Infection
Júlia Leão Batista Simões, Julia Beatrice de Araújo, Margarete Dulce Bagatini
Molecular Neurobiology (2021) Vol. 58, Iss. 10, pp. 5090-5111
Open Access | Times Cited: 12
Understanding and managing the impact of the Covid-19 pandemic and lockdown on patients with multiple sclerosis
Gianmarco Abbadessa, Luigi Lavorgna, Francesca Trojsi, et al.
Expert Review of Neurotherapeutics (2021) Vol. 21, Iss. 7, pp. 731-743
Closed Access | Times Cited: 12
COVID-19 Vaccination Attitudes With Neuromyelitis Optica Spectrum Disorders: Vaccine Hesitancy and Coping Style
Yafang Xu, Yanpei Cao, Yue Ma, et al.
Frontiers in Neurology (2021) Vol. 12
Open Access | Times Cited: 12
COVID-19 severity among patients with multiple sclerosis treated with cladribine: A systematic review and meta-analysis
Angela Albanese, Maria Pia Sormani, Giovanni Gattorno, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 68, pp. 104156-104156
Open Access | Times Cited: 8
Outcome of COVID-19 Infection in Patients With Multiple Sclerosis Who Received Disease-Modifying Therapies: A Systematic Review and Meta-Analysis
Ning Liu, Wuhan Yu, Mengjiao Sun, et al.
Journal of Clinical Neurology (2023) Vol. 19, Iss. 4, pp. 381-381
Open Access | Times Cited: 4
Infection Risk Associated with High‐Efficacy Disease‐Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study
Jieni Li, George J. Hutton, Tyler J. Varisco, et al.
Clinical Pharmacology & Therapeutics (2024)
Open Access | Times Cited: 1
Alemtuzumab in Covid era
Aniello Iovino, Nunzio Olivieri, Francesco Aruta, et al.
Multiple Sclerosis and Related Disorders (2021) Vol. 51, pp. 102908-102908
Open Access | Times Cited: 11
Expert Consensus and Narrative Review on the Management of Multiple Sclerosis in the Arabian Gulf in the COVID-19 Era: Focus on Disease-Modifying Therapies and Vaccination Against COVID-19
Jihad Inshasi, Raed Alroughani, Abdullah Al‐Asmi, et al.
Neurology and Therapy (2021) Vol. 10, Iss. 2, pp. 539-555
Open Access | Times Cited: 11
Era of COVID-19 in Multiple Sclerosis Care
Jonathan D. Krett, Amber Salter, Scott D. Newsome
Neurologic Clinics (2023) Vol. 42, Iss. 1, pp. 319-340
Open Access | Times Cited: 4
Challenges of Equitable Vaccine Distribution in the COVID-19 Pandemic
Jae‐Sung Bae, Darshan Gandhi, Jil Kothari, et al.
arXiv (Cornell University) (2020)
Open Access | Times Cited: 10
Multiple sclerosis immunomodulatory therapies tested for effectiveness in COVID-19
Bożena Adamczyk, Natalia Morawiec, Monika Arendarczyk, et al.
Neurologia i Neurochirurgia Polska (2021) Vol. 55, Iss. 4, pp. 357-368
Open Access | Times Cited: 10
Envisioning Post-pandemic Digital Neurological, Psychiatric and Mental Health Care
Amit Khanna, Graham B. Jones
Frontiers in Digital Health (2021) Vol. 3
Open Access | Times Cited: 10
Thermal dysregulation in patients with multiple sclerosis during SARS-CoV-2 infection. The potential therapeutic role of exercise
Omid Razi, Bakhtyar Tartibian, Ana Teixeira, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 59, pp. 103557-103557
Open Access | Times Cited: 6

Scroll to top